CN116096740A - 经改造t细胞受体和使用方法 - Google Patents

经改造t细胞受体和使用方法 Download PDF

Info

Publication number
CN116096740A
CN116096740A CN202180057372.6A CN202180057372A CN116096740A CN 116096740 A CN116096740 A CN 116096740A CN 202180057372 A CN202180057372 A CN 202180057372A CN 116096740 A CN116096740 A CN 116096740A
Authority
CN
China
Prior art keywords
tcr
polypeptide
seq
amino acid
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180057372.6A
Other languages
English (en)
Chinese (zh)
Inventor
余嘉诚
潘科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN116096740A publication Critical patent/CN116096740A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CN202180057372.6A 2020-06-09 2021-06-08 经改造t细胞受体和使用方法 Pending CN116096740A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036539P 2020-06-09 2020-06-09
US63/036,539 2020-06-09
PCT/US2021/036443 WO2021252517A1 (en) 2020-06-09 2021-06-08 Engineered t cell receptors and methods of use

Publications (1)

Publication Number Publication Date
CN116096740A true CN116096740A (zh) 2023-05-09

Family

ID=78845879

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180057372.6A Pending CN116096740A (zh) 2020-06-09 2021-06-08 经改造t细胞受体和使用方法

Country Status (6)

Country Link
US (1) US20230227526A1 (https=)
EP (1) EP4161555A4 (https=)
JP (1) JP7827645B2 (https=)
CN (1) CN116096740A (https=)
CA (1) CA3186594A1 (https=)
WO (1) WO2021252517A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120718134A (zh) * 2025-08-25 2025-09-30 北京立康生命科技有限公司 靶向col6a3肽的t细胞受体及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105001339A (zh) * 2010-03-19 2015-10-28 伊玛提克斯生物技术有限公司 包括胃肠癌和胃癌的几种肿瘤的新型免疫疗法
WO2017193104A1 (en) * 2016-05-06 2017-11-09 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for mart-1
WO2019036688A1 (en) * 2017-08-18 2019-02-21 Gritstone Oncology, Inc. ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS
US20190321401A1 (en) * 2018-04-05 2019-10-24 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050010030A1 (en) * 2003-07-02 2005-01-13 Zang Jingwu Z. T cell receptor CDR3 sequence and methods for detecting and treating rheumatoid arthritis
IL290655B2 (en) * 2014-05-29 2024-05-01 Us Health Anti-human papillomavirus 16 E7 T-cell chelates
EP3156067A1 (en) * 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin High avidity hpv t-cell receptors
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
TW201835100A (zh) * 2017-02-06 2018-10-01 國立研究開發法人國立癌症研究中心 新穎ｔ細胞受體
EP4219543A1 (en) * 2017-11-06 2023-08-02 Immatics Biotechnologies GmbH Novel engineered t cell receptors and immune therapy using the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105001339A (zh) * 2010-03-19 2015-10-28 伊玛提克斯生物技术有限公司 包括胃肠癌和胃癌的几种肿瘤的新型免疫疗法
WO2017193104A1 (en) * 2016-05-06 2017-11-09 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for mart-1
WO2019036688A1 (en) * 2017-08-18 2019-02-21 Gritstone Oncology, Inc. ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS
US20190321401A1 (en) * 2018-04-05 2019-10-24 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
CN112566698A (zh) * 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEIKE HUTT等: "Affinity Maturation and Validation of a COL6A3-002-Specific T Cell Receptor for Improving Performance in Adoptive Cell Therapy", PROTEIN ENGINEERING SUMMIT, 16 November 2018 (2018-11-16), pages 118 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120718134A (zh) * 2025-08-25 2025-09-30 北京立康生命科技有限公司 靶向col6a3肽的t细胞受体及其用途
CN120718134B (zh) * 2025-08-25 2025-12-26 北京立康生命科技有限公司 靶向col6a3肽的t细胞受体及其用途

Also Published As

Publication number Publication date
EP4161555A4 (en) 2024-06-19
EP4161555A1 (en) 2023-04-12
JP2023530245A (ja) 2023-07-14
CA3186594A1 (en) 2021-12-16
WO2021252517A1 (en) 2021-12-16
JP7827645B2 (ja) 2026-03-10
US20230227526A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
JP7785696B2 (ja) 操作されたｔ細胞受容体および使用の方法
WO2023076875A1 (en) Methods and compositions for treating glioblastoma
JP7827645B2 (ja) 操作されたｔ細胞受容体および使用の方法
TWI893070B (zh) 經工程化之t細胞受體及使用方法
US20260007698A1 (en) Peptides and engineered t cell receptors targeting vcy antigen and methods of use
US20250073333A1 (en) Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
US20250289866A1 (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
CN118302176A (zh) 靶向mage-a4抗原的肽和经改造t细胞受体及使用方法
JP2024539273A (ja) Ｍａｇｅ－ａ４抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
CN117425482A (zh) 靶向egfr抗原的经改造t细胞受体和使用方法
WO2025096983A1 (en) Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use
HK40113193A (zh) 靶向ndc80抗原的肽和经改造t细胞受体及使用方法
WO2025101705A1 (en) Peptides and engineered t cell receptors targeting a melanoma antigen preferentially expressed in tumors antigen and methods of use
HK40092477A (zh) 经改造t细胞受体和使用方法
WO2026019786A1 (en) Peptides and engineered t cell receptors targeting brachyury antigen and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092477

Country of ref document: HK